resTORbio is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio's lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caused by immunosenescence, the decline in immune function that occurs during aging.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/30/17 | $40,000,000 | Series B |
Fidelity Management & Research Company Nest.Bio Ventures OrbiMed Advisors  Quan Capital Rock Springs Capital | undisclosed |
